| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF PI Poulikakos, C Zhang, G Bollag, KM Shokat, N Rosen Nature 464 (7287), 427-430, 2010 | 2076 | 2010 |
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ... Nature 480 (7377), 387-390, 2011 | 1695 | 2011 |
| Targeting RAS–ERK signalling in cancer: promises and challenges AA Samatar, PI Poulikakos Nature reviews Drug discovery 13 (12), 928-942, 2014 | 1209 | 2014 |
| Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas P Lito, CA Pratilas, EW Joseph, M Tadi, E Halilovic, M Zubrowski, ... Cancer cell 22 (5), 668-682, 2012 | 621 | 2012 |
| mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ... Cancer discovery 1 (3), 248-259, 2011 | 525 | 2011 |
| BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition Z Yao, NM Torres, A Tao, Y Gao, L Luo, Q Li, E de Stanchina, ... Cancer cell 28 (3), 370-383, 2015 | 520 | 2015 |
| The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner EW Joseph, CA Pratilas, PI Poulikakos, M Tadi, W Wang, BS Taylor, ... Proceedings of the National Academy of Sciences 107 (33), 14903-14908, 2010 | 519 | 2010 |
| Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis R Chakraborty, OA Hampton, X Shen, SJ Simko, A Shih, H Abhyankar, ... Blood, The Journal of the American Society of Hematology 124 (19), 3007-3015, 2014 | 457 | 2014 |
| New perspectives for targeting RAF kinase in human cancer Z Karoulia, E Gavathiotis, PI Poulikakos Nature Reviews Cancer 17 (11), 676-691, 2017 | 391 | 2017 |
| Mutant BRAF melanomas—dependence and resistance PI Poulikakos, N Rosen Cancer cell 19 (1), 11-15, 2011 | 301 | 2011 |
| RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model S Mabuchi, DA Altomare, M Cheung, L Zhang, PI Poulikakos, HH Hensley, ... Clinical cancer research 13 (14), 4261-4270, 2007 | 293 | 2007 |
| Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells HQ Wang, DA Altomare, KL Skele, PI Poulikakos, FP Kuhajda, ... Oncogene 24 (22), 3574-3582, 2005 | 239 | 2005 |
| Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK PI Poulikakos, GH Xiao, R Gallagher, S Jablonski, SC Jhanwar, JR Testa Oncogene 25 (44), 5960-5968, 2006 | 207 | 2006 |
| An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling Z Karoulia, Y Wu, TA Ahmed, Q Xin, J Bollard, C Krepler, X Wu, C Zhang, ... Cancer cell 30 (3), 485-498, 2016 | 197 | 2016 |
| SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors TA Ahmed, C Adamopoulos, Z Karoulia, X Wu, R Sachidanandam, ... Cell reports 26 (1), 65-78. e5, 2019 | 183 | 2019 |
| Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity N Ishii, N Harada, EW Joseph, K Ohara, T Miura, H Sakamoto, Y Matsuda, ... Cancer research 73 (13), 4050-4060, 2013 | 183 | 2013 |
| Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis R Chakraborty, TM Burke, OA Hampton, DJ Zinn, KPH Lim, H Abhyankar, ... Blood, The Journal of the American Society of Hematology 128 (21), 2533-2537, 2016 | 159 | 2016 |
| Resistance to MEK inhibitors: should we co-target upstream? PI Poulikakos, DB Solit Science signaling 4 (166), pe16-pe16, 2011 | 143 | 2011 |
| Personalized preclinical trials in BRAF inhibitor–resistant patient-derived xenograft models identify second-line combination therapies C Krepler, M Xiao, K Sproesser, PA Brafford, B Shannan, M Beqiri, Q Liu, ... Clinical Cancer Research 22 (7), 1592-1602, 2016 | 135 | 2016 |
| Human follicle-stimulating hormone (FSH) receptor interacts with the adaptor protein APPL1 in HEK 293 cells: potential involvement of the PI3K pathway in FSH signaling CA Nechamen, RM Thomas, BD Cohen, G Acevedo, PI Poulikakos, ... Biology of Reproduction 71 (2), 629-636, 2004 | 135 | 2004 |
David SolitCo-Director, Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα mskcc.org
